<DOC>
	<DOCNO>NCT01608776</DOCNO>
	<brief_summary>To evaluate safety effectiveness MIST Therapy conjunction Standard Care ( SOC ) compare Standard Care alone treatment diabetic foot ulcer ( DFU ) .</brief_summary>
	<brief_title>RESPOND Restoring Equilibrium Wound Stimulation Promote Healing Of Non-healing DFUs</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Male female subject race least 18 90 year old Lower extremity full thickness diabetic foot ulcer 30364 day duration Subject 's wound must 2cm² 20cm² screening Subject 's wound must malleolus Documented ABI 0.8 1.2 study limb transcutaneous partial pressure oxygen ( TcpO2 ) &gt; 40 mmHG ; toe pressure &gt; 40 mmHG ; Doppler waveform consistent adequate flow foot ( biphasic triphasic waveform ) within 30 day screen . Subject subject 's legally authorize representative understands nature procedure ( ) provide write informed consent prior study enrollment Subject willing able comply specify care visit requirement Subject and/or caregiver must willing able learn perform duty dress change , demonstrate ability . Index ulcer wound expose tendon , ligament , muscle , bone Index ulcer wound present clinical sign acute infection , suspect known Subjects evidence osteomyelitis cellulitis gangrene study limb Subjects active Charcot 's foot study limb Subjects amputation Trans Metatarsal Amputation ( TMA ) affect limb Subjects active malignancy study limb except nonmelanoma skin cancer Subjects plan vascular surgery , angioplasty thrombolysis procedure within study period Subjects within 6 week postoperatively vascular procedure . Subject prior skin replacement , negative pressure therapy , ultrasound therapy apply index wind 14 day prior screen Subjects receive oral , IV antibiotic/antimicrobial agent medication use within 2 day ( 48 hour ) baseline . Subjects received topical antibiotic/antimicrobial agent dressing index wound site within 2 day ( 48 hour ) baseline . Subjects currently take steroid &gt; 10mg dosage Subject receive growth factor therapy ( e.g. , autologous plateletrich plasma gel , becaplermin , bilayered cell therapy , dermal substitute , extracellular matrix ) within 14 day screen date . Subject currently receive receive radiation chemotherapy within 3 month randomization . Subject one medical condition ( ) , uncontrolled diabetes ( HbA1c &gt; 12 ) , renal , hepatic , hematologic , neurologic , immune disease opinion investigator would make subject inappropriate study candidate Subject allergic broad spectrum primary &amp; secondary dressing material , include occlusive dressing adhesives dressing . Female subject pregnant refuse utilize adequate contraceptive method childbearing age trial . Subject know suffer disorder situation subject investigator feel would interfere compliance study requirement Subject currently enrol enrol last 30 day another investigational device drug trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>